The estimated Net Worth of Venture Management Co Iii L... is at least $10.9 millió dollars as of 17 December 2004. Venture L owns over 26,500 units of Alnylam Pharmaceuticals Inc stock worth over $9,633,836 and over the last 20 years Venture sold ALNY stock worth over $1,290,725.
Venture has made over 3 trades of the Alnylam Pharmaceuticals Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Venture sold 26,500 units of ALNY stock worth $177,285 on 17 December 2004.
The largest trade Venture's ever made was selling 100,000 units of Alnylam Pharmaceuticals Inc stock on 3 December 2004 worth over $680,000. On average, Venture trades about 63,167 units every 5 days since 2004. As of 17 December 2004 Venture still owns at least 36,783 units of Alnylam Pharmaceuticals Inc stock.
You can see the complete history of Venture L stock trades at the bottom of the page.
Over the last 20 years, insiders at Alnylam Pharmaceuticals Inc have traded over $140,068,015 worth of Alnylam Pharmaceuticals Inc stock and bought 4,419,116 units worth $1,983,132,563 . The most active insiders traders include Sanofi, Christoph H Westphal és Kevin P Starr. On average, Alnylam Pharmaceuticals Inc executives and independent directors trade stock every 23 days with the average trade being worth of $11,181,724. The most recent stock trade was executed by Yvonne Greenstreet on 20 August 2024, trading 15,000 units of ALNY stock currently worth $1,275,000.
alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.
Alnylam Pharmaceuticals Inc executives and other stock owners filed with the SEC include: